phentermine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anorexics | 2140 | 122-09-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 15 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 4.19 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Hosey CM, Chan R, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 4, 1959 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cholecystitis chronic | 160.48 | 16.90 | 58 | 6077 | 10441 | 46669486 |
| Injury | 88.72 | 16.90 | 61 | 6074 | 43966 | 46635961 |
| Angle closure glaucoma | 74.24 | 16.90 | 22 | 6113 | 2117 | 46677810 |
| Gallbladder disorder | 73.82 | 16.90 | 39 | 6096 | 17459 | 46662468 |
| Anxiety | 67.47 | 16.90 | 100 | 6035 | 181857 | 46498070 |
| Phospholipidosis | 59.79 | 16.90 | 10 | 6125 | 61 | 46679866 |
| Emotional distress | 58.21 | 16.90 | 41 | 6094 | 30666 | 46649261 |
| Carotid artery dissection | 56.60 | 16.90 | 11 | 6124 | 169 | 46679758 |
| Arteriospasm coronary | 55.28 | 16.90 | 20 | 6115 | 3601 | 46676326 |
| Drug abuse | 48.07 | 16.90 | 50 | 6085 | 63358 | 46616569 |
| Cholelithiasis | 47.70 | 16.90 | 40 | 6095 | 38641 | 46641286 |
| Subarachnoid haemorrhage | 41.83 | 16.90 | 23 | 6112 | 11130 | 46668797 |
| Pregnancy | 39.67 | 16.90 | 31 | 6104 | 27106 | 46652821 |
| Encephalomalacia | 30.36 | 16.90 | 8 | 6127 | 500 | 46679427 |
| Deep vein thrombosis | 29.69 | 16.90 | 44 | 6091 | 79729 | 46600198 |
| Spinal cord infarction | 29.39 | 16.90 | 7 | 6128 | 289 | 46679638 |
| Psoriasis | 27.32 | 16.90 | 42 | 6093 | 78562 | 46601365 |
| Stress cardiomyopathy | 26.32 | 16.90 | 15 | 6120 | 7769 | 46672158 |
| Depression | 25.82 | 16.90 | 64 | 6071 | 170040 | 46509887 |
| Paraesthesia | 25.50 | 16.90 | 51 | 6084 | 117386 | 46562541 |
| Colitis ischaemic | 25.13 | 16.90 | 16 | 6119 | 10116 | 46669811 |
| Renal vein thrombosis | 24.27 | 16.90 | 6 | 6129 | 290 | 46679637 |
| Biliary dyskinesia | 23.49 | 16.90 | 10 | 6125 | 2763 | 46677164 |
| Pain | 22.22 | 16.90 | 122 | 6013 | 476826 | 46203101 |
| Suicidal ideation | 20.82 | 16.90 | 31 | 6104 | 56351 | 46623576 |
| Pneumonia | 20.57 | 16.90 | 12 | 6123 | 376308 | 46303619 |
| Anhedonia | 20.03 | 16.90 | 14 | 6121 | 10321 | 46669606 |
| Device dislocation | 17.96 | 16.90 | 18 | 6117 | 21784 | 46658143 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug abuse | 54.10 | 27.53 | 32 | 835 | 82040 | 29869571 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A08AA01 | ALIMENTARY TRACT AND METABOLISM ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS Centrally acting antiobesity products |
| FDA PE | N0000175372 | Appetite Suppression |
| FDA EPC | N0000175423 | Sympathomimetic Amine Anorectic |
| FDA PE | N0000175651 | Increased Sympathetic Activity |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D019440 | Anti-Obesity Agents |
| MeSH PA | D001067 | Appetite Depressants |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D000697 | Central Nervous System Stimulants |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D013566 | Sympathomimetics |
| CHEBI has role | CHEBI:35337 | analeptic drug |
| CHEBI has role | CHEBI:35470 | cns agent |
| CHEBI has role | CHEBI:35524 | sympathomimetic |
| CHEBI has role | CHEBI:37962 | adrenergic neuron agents |
| CHEBI has role | CHEBI:48560 | dopamine agents |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Low blood pressure | indication | 45007003 | |
| Obesity | indication | 414916001 | DOID:9970 |
| Prevention of Hypotension During Spinal Anesthesia | indication | ||
| Hypotension Secondary to Spinal Anesthesia | indication | ||
| Heart valve disorder | contraindication | 368009 | DOID:4079 |
| Alcoholism | contraindication | 7200002 | |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Feeling agitated | contraindication | 24199005 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Mild pre-eclampsia | contraindication | 41114007 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Diabetes mellitus type 1 | contraindication | 46635009 | DOID:9744 |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Substance abuse | contraindication | 66214007 | |
| Psychotic disorder | contraindication | 69322001 | |
| Pulmonary hypertension | contraindication | 70995007 | DOID:6432 |
| Secondary glaucoma | contraindication | 95717004 | |
| Angina pectoris | contraindication | 194828000 | |
| Edema | contraindication | 267038008 | |
| Syncope | contraindication | 271594007 | |
| Arteriosclerosis obliterans | contraindication | 361133006 | DOID:5160 |
| Hypertensive urgency | contraindication | 443482000 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.92 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium-dependent noradrenaline transporter | Transporter | INHIBITOR | WOMBAT-PK | CHEMBL | |||||
| Sodium-dependent dopamine transporter | Transporter | Ki | 5.80 | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4019891 | VUID |
| N0000147976 | NUI |
| D05458 | KEGG_DRUG |
| 1197-21-3 | SECONDARY_CAS_RN |
| 4018166 | VANDF |
| 4018167 | VANDF |
| 4019891 | VANDF |
| C0013326 | UMLSCUI |
| CHEBI:8080 | CHEBI |
| CHEMBL1574 | ChEMBL_ID |
| CHEMBL1200912 | ChEMBL_ID |
| D010645 | MESH_DESCRIPTOR_UI |
| DB00191 | DRUGBANK_ID |
| 4771 | PUBCHEM_CID |
| 7269 | IUPHAR_LIGAND_ID |
| 1064 | INN_ID |
| C045TQL4WP | UNII |
| 221138 | RXNORM |
| 1294 | MMSL |
| 41147 | MMSL |
| 5278 | MMSL |
| 5279 | MMSL |
| d00806 | MMSL |
| 001864 | NDDF |
| 001865 | NDDF |
| 001866 | NDDF |
| 373343009 | SNOMEDCT_US |
| 426428004 | SNOMEDCT_US |
| 53480001 | SNOMEDCT_US |
| 6394006 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| phentermine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0644 | CAPSULE | 15 mg | ORAL | ANDA | 29 sections |
| phentermine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0647 | CAPSULE | 30 mg | ORAL | ANDA | 29 sections |
| phentermine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-5000 | CAPSULE | 30 mg | ORAL | ANDA | 29 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-0597 | CAPSULE | 30 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1308 | CAPSULE | 30 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1310 | CAPSULE | 30 mg | ORAL | ANDA | 26 sections |
| Phentermine ResinER | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1366 | CAPSULE, EXTENDED RELEASE | 30 mg | ORAL | ANDA | 26 sections |
| Phentermine ResinER | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1398 | CAPSULE, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1438 | CAPSULE | 30 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1445 | TABLET | 37.50 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1742 | CAPSULE | 15 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1743 | CAPSULE | 37.50 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-098 | CAPSULE | 30 mg | ORAL | ANDA | 26 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-099 | CAPSULE | 15 mg | ORAL | ANDA | 9 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-116 | TABLET | 37.50 mg | ORAL | ANDA | 9 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-552 | TABLET | 30 mg | ORAL | ANDA | 31 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-592 | CAPSULE | 37.50 mg | ORAL | ANDA | 9 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-593 | CAPSULE | 30 mg | ORAL | ANDA | 19 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-602 | TABLET | 37.50 mg | ORAL | ANDA | 19 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-620 | CAPSULE | 30 mg | ORAL | ANDA | 9 sections |
| LOMAIRA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-001 | TABLET | 8 mg | ORAL | ANDA | 17 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-025 | TABLET | 37.50 mg | ORAL | ANDA | 25 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-025 | TABLET | 37.50 mg | ORAL | ANDA | 25 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-026 | CAPSULE | 15 mg | ORAL | ANDA | 29 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-027 | CAPSULE | 30 mg | ORAL | ANDA | 29 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-028 | CAPSULE | 30 mg | ORAL | ANDA | 29 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-029 | CAPSULE | 37.50 mg | ORAL | ANDA | 25 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-029 | CAPSULE | 37.50 mg | ORAL | ANDA | 25 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-067 | TABLET | 8 mg | ORAL | ANDA | 17 sections |
| Phentermine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 11534-157 | CAPSULE | 15 mg | ORAL | ANDA | 28 sections |